Orion gains on strong Q1 results, driven by sales of Nubeqa

Orion Oyj

23/04/2025 12:07

April 23 (Reuters) -    ** Shares in Orion ORNBV.HE are up 3.5% after the Finnish drugmaker posted Q1 results ahead of consensus with EBIT of 77.9 million euros, 9% beat, driven by sales of its prostate cancer treatment jointly developed by Orion and Bayer

   ** The company's Q1 sales of 354.6 million euros  ($404.39 million)were 3% ahead of company-collated consensus, with Nubeqa's product sales at an all-time high so far

   ** "We remain optimistic on Nubeqa's ability to outperform and set into motion a series of outlook upgrades over the quarters," says Jefferies

   ** The brokerage adds that key focus will be implications of potential pharma tariffs on Nubeqa orders from Bayer and updates on pipeline

   ** Including today's rise the stock has gained 15.05% YTD​

($1 = 0.8769 euros)

 (Reporting by Agnieszka Gosciak-Rabalska)

 ((Agnieszka.gosciak@thomsonreuters.com))